Clinical Trials

Phase 3 Not yet recruiting

264 enrolled

Myasthenia Gravis

NCT07463521 2026-03-17

MyVision

120 enrolled

Myasthenia Gravis

NCT06607627 2026-03-16

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Myasthenia Gravis

NCT06700616 2026-03-16

MG Cohort

Active not recruiting

1,199 enrolled

Myasthenia Gravis

NCT06987539 2026-03-16

THYME

Phase 2 Recruiting

15 enrolled

Myasthenia Gravis

NCT05265273 2026-03-13

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Phase 3 Enrolling by invitation

Myasthenia Gravis

NCT06435312 2026-03-13

ziMyG+

8 enrolled

Myasthenia Gravis

NCT06909253 2026-03-13

MG-ARCADIA

50 enrolled

Myasthenia Gravis

NCT07217587 2026-03-13

EPIC

115 enrolled

Myasthenia Gravis

NCT07246564 2026-03-13

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Phase 4 Recruiting

40 enrolled

Myasthenia Gravis

NCT07247279 2026-03-13

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Phase 3 Not yet recruiting

450 enrolled

Myasthenia Gravis, Rare Diseases

NCT07465289 2026-03-11

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

100 enrolled

Myasthenia Gravis

NCT04524273 2026-03-10

MINT

238 enrolled 36 charts

Myasthenia Gravis

NCT06414954 2026-03-10

SYNAPSE-MG

Phase 2 Recruiting

84 enrolled

Myasthenia Gravis

NCT06456580 2026-03-10

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Phase 1 Not yet recruiting

180 enrolled

Myasthenia Gravis

NCT07304154 2026-03-10

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT05403541 2026-03-06

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

240 enrolled

Myasthenia Gravis

NCT07039916 2026-03-06

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

231 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT04951622 2026-03-03

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Phase 4 Not yet recruiting

199 enrolled 11 charts

Myasthenia Gravis

NCT07221838 2026-03-03

OCTAGON

75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT06055959 2026-02-27

ziMyG

8 enrolled

Myasthenia Gravis

NCT06149559 2026-02-27

roMyG

Phase 3 Enrolling by invitation

Myasthenia Gravis

NCT06540144 2026-02-27

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Myasthenia Gravis

NCT06680037 2026-02-27

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Phase 1 Recruiting

32 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1 Recruiting

30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT06517758 2026-02-24

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

146 enrolled

Myasthenia Gravis

NCT06744920 2026-02-20

RELIEVE

180 enrolled

Myasthenia Gravis

NCT05644561 2026-02-19

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Myasthenia Gravis

NCT04202341 2026-02-18

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

500 enrolled

Myasthenia Gravis

NCT04833894 2026-02-18

ADAPT Jr

Myasthenia Gravis

NCT07294170 2026-02-18

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

70 enrolled

Myasthenia Gravis

NCT06298565 2026-02-17

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

680 enrolled

Myasthenia Gravis

NCT06299748 2026-02-17

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

279 enrolled

Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06799247 2026-02-13

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

100 enrolled

Myasthenia Gravis

NCT05070858 2026-02-12

NIMBLE

288 enrolled

Myasthenia Gravis

NCT06965309 2026-02-12

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Phase NA Terminated

9 enrolled

Myasthenia Gravis

NCT07250750 2026-02-11

Synergy-MG

Phase 1/2 Recruiting

96 enrolled

Myasthenia Gravis

NCT06220201 2026-02-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Phase 1 Recruiting

120 enrolled

Multiple Sclerosis, Myasthenia Gravis

NCT07284420 2026-02-09

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Phase 2 Recruiting

70 enrolled

Myasthenia Gravis

NCT06704269 2026-02-05

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Phase 1/2 Recruiting

15 enrolled

Myasthenia Gravis

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Phase 2/3 Enrolling by invitation

40 enrolled

Myasthenia Gravis

NCT05374590 2026-02-02

ADAPT Jr +

Myasthenia Gravis

NCT06193889 2026-01-30

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT07033559 2026-01-28

Detecting Fatigue From Voice in Generalised Myasthenia Gravis

Not yet recruiting

240 enrolled

Fatigue, Myasthenia Gravis

NCT05556096 2026-01-23

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

261 enrolled

Myasthenia Gravis

NCT04818671 2026-01-22

ADAPTSC+

Phase 3 Completed

184 enrolled 22 charts

Myasthenia Gravis

NCT06764160 2026-01-15

ECU-MG-304

Phase 3 Completed

15 enrolled

Myasthenia Gravis

NCT07249632 2026-01-15

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Phase NA Active not recruiting

120 enrolled

Myasthenia Gravis

NCT05150210 2025-12-23

SP Thoracic IDE Study

32 enrolled 8 charts

Thoracic

Myasthenia Gravis, Thymoma

NCT06558279 2025-12-15

ADAPT oculus